Is Arcutis Biotherapeutics (ARQT) stock Halal?

Arcutis Biotherapeutics is a biopharmaceutical company dedicated to developing and commercializing innovative treatments for dermatological diseases and conditions. Primarily focused on enhancing therapies for skin diseases, Arcutis aims to improve the standard of care in dermatology through the use of its proprietary technologies and formulation science expertise. For Muslim investors, though, the most pressing question is simpler: is Arcutis Biotherapeutics a Halal investment?

Is Arcutis Biotherapeutics Shariah compliant?

Yes. In the October 2026 screening Arcutis Biotherapeutics (ARQT) passes AAOIFI Shariah Standard No. 21: the business activity screen and every financial ratio screen hold. Technology companies rarely fail AAOIFI screening on what they sell. Software, hardware and digital services are permissible business activities, so for a company like Arcutis Biotherapeutics the Shariah question moves to the balance sheet: how much of its market value sits in interest bearing debt, how much of its cash earns Riba in conventional deposits, and whether incidental income from impermissible sources creeps past 5% of revenue. These are exactly the ratios AAOIFI Shariah Standard No. 21 polices, and they move every month with the share price.

Does Arcutis Biotherapeutics pass the business activity test?

Yes. In the October 2026 screening Arcutis Biotherapeutics holds an overall PASS, which a stock only earns when its core business clears the activity screen. The watch item for technology names is incidental: cash returns and platform content can carry impermissible elements, which AAOIFI tolerates only below the thresholds.

Is Arcutis Biotherapeutics' income Halal?

Yes, within AAOIFI's tolerance. Arcutis Biotherapeutics' income from non-permissible sources stays below 5% of revenue in the October 2026 screening, and the small impure portion is handled through purification: the factor of 98.28% tells holders of ARQT what share of each dividend to keep and what remainder to donate to charity. On a dividend yield of around None, the purification amount is modest but real.

Does Arcutis Biotherapeutics meet AAOIFI's debt and investment ratio requirements?

Yes. Both caps hold this month: interest bearing investments and interest bearing debt each stay below 30% of market capitalisation, measured against a market capitalisation of $3.32B (market data as of 1 October 2026). Because the caps move with the share price, our Shariah Supervisory Board has ARQT re-screened every month, and the result above always shows the latest verdict.

Why do other halal screeners show a different verdict for Arcutis Biotherapeutics?

Screeners can disagree without either being wrong. AAOIFI Shariah Standard No. 21, which Tabadulat applies, measures interest bearing debt and investments against market capitalisation with a 30% ceiling. MSCI and FTSE measure them against total assets with a 33% ceiling, and S&P and Dow Jones Islamic use a multi year average of market capitalisation. Data dates differ too, because each provider reads filings and prices on its own schedule. The same company can therefore pass one standard and fail another in the same month. Tabadulat publishes one answer, the AAOIFI result as of October 2026, and re-screens it every month.

Tabadulat is an ADGM regulated brokerage whose license covers Shari'a Compliant Regulated Activities, as the FSRA permission names them. New to the terminology? Gharar and Maysir, Sukuk, Zakat and purification are all explained in plain English.

New to the screening method? Read Why a Halal Stock Screener Matters for Halal Investing